drugset / Trial / NCT05926882

Efficacy of Oral Apremilast in the Treatment of Alopecia Areata at the Tertiary Care Hospital, Karachi.

NCT05926882

Phase 4 Completed 30 enrolled Jinnah Postgraduate Medical Centre
NaSingle-groupOpen-labelTreatment

Summary

Alopecia areata (AA) is a disease characterized by hair cycle dysfunction and the presence of peribulbar and perifollicular mononuclear cell infiltrate.1 The majority of patients report the rapid onset of one or several well-defined, usually round, 1 to 4 cm areas of scalp hair loss. A common feature is the presence of "exclamation-mark" hairs that are broken and short hairs that taper proximally. Commonly used treatment modalities are steroids (intra-lesional, topical or systemic), contact immunotherapy, anthraline, minoxidil, calcineurine inhibitors, topical retinoids, systemic immune modulating agents, photo-chemotherapy, dermatography wigs and hypnotherapy etc Apremilast is a newer drug. It is an oral small-molecule inhibitor of phosphodiesterase 4 (PDE4), this may be effective treatment for a variety of inflammatory skin disorders such as alopecia areata.

Timeline

Start
2022-08-01
Primary completion
2023-06-20
Completion
2023-06-20

Drugs

EvaluationDrugModalityDoseRoute
Subject Apremilast Small molecule 30 mg Oral

Indications